Optiver Holding
DNTH icon

Optiver Holding’s Dianthus Therapeutics DNTH Stock Holding History

Optiver Holding’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Buy
246
+36
+17% +$3.14K ﹤0.01% 1446
2026
Q1 		$17.6K Buy
210
+40
+24% +$2.32K ﹤0.01% 1123
2025
Q4 		$7.01K Buy
170
+36
+27% +$1.4K ﹤0.01% 1233
2025
Q3 		$5.27K Buy
+134
New +$3.42K ﹤0.01% 1701

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Optiver Holding's DNTH Position: Q2 2026 in Review

Optiver Holding increased its Dianthus Therapeutics (DNTH) stake by 17% in Q2 2026, buying an estimated $3.14K and bringing the position to 246 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

Optiver Holding first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Optiver Holding held 246 shares of Dianthus Therapeutics worth $24K as of Q2 2026.
  • Optiver Holding bought 36 Dianthus Therapeutics shares in Q2 2026, an estimated $3.14K.
  • Dianthus Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1446 holding.
  • Optiver Holding first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.